Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
|Articles|March 23, 2020
Augury Adds Capabilities to Machine Health Platform
Author(s)BioPharm International Editors
Enhancements to Augury’s AI-based machine health platform include new capabilities and collaboration tools for personnel working remotely.
Advertisement
Augury, which supplies AI-based machine health solutions, launched new capabilities and enhancements for remote monitoring and diagnosis of manufacturing equipment, including pharmaceutical manufacturing. A new feature called Augury Threads is a collaboration tool that allows maintenance teams, reliability experts, and operations teams to share analytics, insights, recommendations, and actions about critical machines from anywhere in the world.
Other improvements to the Augury platform include remote diagnostics, such as improved machine health and anomaly-based alerts, with deeper root cause analysis and prescriptive maintenance recommendations. The company has enhanced remote feedback and troubleshooting with improvements to the speed and functionality of diagnostic feedback on repairs. According to the press release, maintenance actions can be validated in near-real time by logging a repair and initiating a conversation with an Augury machine health expert. The platform offers a remote view of machine history, which can be combined with the new Augury Threads feature as a single place to track the history of a machine’s performance and the expert reliability conversations around it. The new Augury Threads feature is available now to Augury customers using Halo sensors, and all other features are available to all Augury customers, said the company in the
Source:
Advertisement
Related to this article
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5